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ABSTRACT 
 
The research focuses on the development of multiparticulate delivery system for acid-labile Lansoprazole 
to prevent its degradation in the acidic environment of the stomach and enhance its bioavailability via in-
testinal absorption. This problem can be solved by enteric coating. In this project, cellulose acetate phthalate 
a polymer usually utilized for gastrointestinal film coating of tablets, was used to prepare enteric micro-
spheres of lansoprazole with solvent evaporation technique in various formulations such as F1, F2, F3, F4, 
F5 with drug: polymer ratios of 1:1, 1:2, 1:3, 1:4, 1:5 respectively. FTIR study indicated compatibility be-
tween drug and polymer. Increase in concentration of polymer increased spheriocity and mean diameter of 
the microspheres. The drug entrapment efficiency was in the range of 72.23% to 88.64%. SEM revealed that 
microspheres were found spherical and porous. In-vitro study proves that drug release slowly increases as 
the pH of the medium increased and prevents degradation of drug in acidic pH. In-vitro drug release was 
found to be 92.80%, 94.55%, 92.72%, 96.34%, 98.65% in all 5 formulations. All 5 formulations showed gas-
tric resistance around 80-90%. So it is concluded that the developed enteric coated microspheres of Lanso-
prazole prevented drug release in the stomach which would lead to significant improvement in its bioavail-
ability through enhanced intestinal absorption. 
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INTRODUCTION 
Oral drug delivery route is perhaps the preferred way 
to take medicines. Though, their short circulation 
half- life and limited absorption through a specified 
intestine segment restricts several other drugs’ ther-
apeutic effects[1]. Currently, no drug delivery system 
is ideally conductive to achieving all the ambitious 
goals, but genuine efforts have been made to accom-
plish them via novel drug delivery approaches. A 
number of new drug delivery technologies have de-
veloped that include different paths of implementa-
tion to ensure managed and targeted delivery of 
drugs[3]. The focused drug delivery method was de-
signed to try to concentrate the drug in the tissues of 
interest while increasing the overall concentration of 
the drug in the other tissues. The drug is therefore 
placed on the target site. Therefore, the drug does not 
affect the surrounding tissues[2]. Microspheres were 
tiny spherical bodies with just a diameter of 1 to 1000 
in the µm range[4]. Micro particles from different nat-
ural and synthetic components can be produced. It is 
possible to alter the drug behaviour in vivo by mixing 
the drug with a carrier molecule. The carrier’s activity 
drastically alters clearance kinetics, tissue distribu-
tion, metabolism i.e., kinetics and cellular interaction 
of the drug. Using these improvements in the action 
of pharmacodynamics will result in increased thera-
peutic output. A wide range of materials namely im-
munoglobulin serum proteins, liposomes, micro-
spheres, microcapsules, nanoparticles and even cells 
like erythrocytes were also used as drug carriers5. 
Oral microspheres were used to support the release 
of drugs and to reducing or eliminating discomfort of 
the gastrointestinal tract. Moreover, multiparticulate 
delivery systems in the gastrointestinal tract distrib-
uted more evenly. This tends to result in a much more 
reproducible uptake of the drug and lessens local ir-
ritation better than single unit dosage forms along 
with no disintegrating polymer tablets. It is also pos-
sible to avoid excessive intestinal accumulation of the 
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polymeric content which can arise with matrix tab-
lets during chronic dosing[6]. In 1997, microspheres 
were first designed for the drug’s continuous action. 
Micro particles have since proven to also be good fits 
for continued and controlled release of drugs and be-
came an option to conventional or immediate release 
compositions[7]. Such particles also provide the active 
drug ingredients that are pharmacologically active 
but are hard to deliver due to the low water solubility. 
In such kinds of drugs, obtaining the necessary ther-
apeutic concentrations of the medication throughout 
the blood stream is difficult, allowing higher levels of 
Cmax, tmax and area under curve to be achieved[8]. Mi-
crospheres based formulations are capable of releas-
ing a steady amount of drug throughout the blood or 
targeting drugs to specific body sites. While establish-
ing the drug delivery system, some of the key points 
to be taken into account are the type of carrier used, 
the route of administration, the drug delivery target 
and the strategy to improve the therapeutic effective-
ness of the drug. These were all the factors that can 
be minimizing the adverse effects of the active phar-
maceutical entity[9].  
An enteric coating is a polymer barrier applied on 
oral medication that prevents its dissolution or disin-
tegration in the gastric environment[10]. This helps by 
either protecting drugs from the acidity of the stom-
ach, the stomach from the detrimental effects of the 
drug, or to release the drug after the stomach (usually 
in the upper tract of the intestine). Some drugs are 
unstable at the pH of gastric acid, and need to be pro-
tected from degradation. Enteric coating is also an ef-
fective method to obtain drug targeting (such as gas-
tro-resistant drugs)[11]. Other drugs such as some anti 
helminthic may need to reach a high concentration in 
a specific part of the intestine. Enteric coating may 
also be used during studies as a research tool to de-
termine drug absorption. Enteric coated medications 
pertain to the "delayed action" dosage form cate-
gory[12]. From a pharmacological point of view the 
term "enteric coating" is not entirely correct, as gas-
tric resistance can be also obtained by adding enteric 
polymeric systems to the matrix of the dosage form. 
Tablets, mini-tablets, pellets and granules (usually 
filled into capsule shells) are the most common en-
teric-coated dosage forms[13]. 
Some of the enteric coating polymers are[14]: 
• Methyl acrylate-methacrylic acid copolymers 
• Cellulose acetate phthalate (CAP) 
• Cellulose acetate succinate 
• Hydroxypropyl methyl cellulose phthalate 
• Hydroxypropyl methyl cellulose acetate succinate 
(hypromellose acetate succinate) 
• Polyvinyl acetate phthalate (PVAP)[22] 
• Methyl methacrylate-methacrylic acid copoly-
mers 
• Shellac 
• Cellulose acetate trimellitate 
• Sodium alginate[28] 
• Enteric coating aqueous solution (ethyl cellulose, 
medium chain triglycerides (coconut), oleic acid, 
sodium alginate, stearic acid) (coated soft gels) 
MATERIALS AND METHODS 
Materials  
The materials used in this research are Lansoprazole 
procured as gift sample from Hetero drugs Pvt. Ltd, 
Hyderabad, Cellulose acetate phthalate from FMC Bi-
opolymers, Acetone FMC Biopolymers, Span 80, Liq-
uid Paraffin from Ferro industries. 
Method  
Drug excipient compatibility studies: IR spectra of 
drug, drug and polymers and excipients were ob-
tained by using FTIR spectrophotometer. FTIR spec-
tra of pure drug, and its physical mixture were ob-
tained by using KBr pellets methods. About 2% 
(w/w) of samples was mixed with potassium bro-
mide (KBr) disc. Each disc was scanned at a resolu-
tion of 4 cm-1 over a wave number region of 400–
4000 cm-1 by a FTIR spectrometer[15]. 
Standard plot for Lansoprazole 
Acid buffer (pH 1.2) 
Accurately weighed 100mg of Lansoprazole was 
taken in 100ml of volumetric flask. Dissolve and 
makeup the volume with pH 1.2 buffer solution. Take 
10ml of this solution in a 100ml of volumetric flask 
and makeup the volume with pH 1.2 buffer solution 
to get working with stock solution.  
Table 1: Standard calibration table of Lansoprazole 
S.no Concentration 
(µg/ml) 
Absorbance at 284 nm 
pH 1.2 pH 6.8 
1 0 0 0 
2 0.2 0138±0.02 0.085±0.03 
3 0.4 0.266±0.01 0.149±0.05 
4 0.6 0.407±0.03 0.243±0.01 
5 0.8 0.535±0.04 0.305±0.02 
6 1 0.661±0.02 0.468±0.03 
From this stock solution aliquots 0.2ml, 0.4ml, 0.6ml, 
0.8ml and 1ml were pipetted out into a series of 10ml 
volumetric flasks and makeup to mark with pH 1.2 
buffer solution in order to get concentration. The ab-
sorbance of the resulting solution was then measured 
at 284nm using UV spectrophotometer against re-
spective parent solvent as a blank. The standard 
curve was obtained by plotting absorbance vs. con-
centration in µg/ml[16].  
Phosphate buffer (pH 6.8) 
Accurately weighed 100mg of Lansoprazole was dis-
solved in 100ml of pH 6.8 phosphate buffer solution. 
Take 10ml of this solution in a 100ml of volumetric 
flask and makeup the volume with phosphate buffer 
(pH 6.8) solution to get working with stock-solu-
tion[16]. From this stock solution aliquots of 0.2ml, 
0.4ml, 0.6ml, 0.8ml, and 1ml were pipetted out into a 
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series of 10ml volumetric flasks and makeup to the 
mark with pH 6.8 phosphate buffer solution in order 
to get concentration.  
The absorbance of the resulting solution was then 
measured at 284nm using UV spectrophotometer 
against respective parent solvent as a blank (i.e. pH 
6.8 buffer solution). The standard curve was obtained 
by plotting absorbance vs. concentration in µg/ml. 
 
Figure 1: Standard calibration curve of Lansoprazole 
at pH 1.2 
 
Figure 2: Standard calibration curve of Lansoprazole 
at pH 6.8 
Formulation and development of Lansoprazole 
microspheres 
Solvent evaporation method 
Microspheres were prepared by using solvent evapo-
ration method. Cellulose acetate phthalate was dis-
solved in acetone at different concentrations. Light 
mineral oil with 1%(w/v) of span 80 was placed in a 
beaker and mixed at 400 rpm using two-bladed pro-
peller stirrer. Drug was dispersed in polymer solution 
at different ratios of 1:1, 1:2, 1:3, 1:4 and 1:5. Subse-
quently, this mixture was poured into the oil phase 
and mixed until all solvent was evaporated at room 
temperature. Microspheres were filtered, washed 
with ether and collected. The detailed composition of 
the various formulations prepared is mentioned in 
(Table 2). 
Evaluation parameters of microspheres 
Particle size analysis 
Particle size analysis of drug-loaded microspheres 
was performed by optical microscopy. A small 
amount of microspheres were suspended in purified 
water (10ml). Mount the sample on a clean glass slide 
and placed it on mechanical stage of the microscope. 
The eye piece of the microscope fitted with a microm-
eter by which the size of the spheres could be ap-
peared. This process was repeated for each batch of 
prepared microspheres[20]. 
Surface morphology 
The surface morphological details of the micro-
spheres were determined by using a scanning elec-
tron microscope (SEM) model JSM, 35CF JEOL, Japan. 
The samples were dried thoroughly in vacuum desic-
cator before mounting on brass specimen studies. 
The samples were mounted on a specimen studies us-
ing double sided adhesive tape and gold-palladium al-
loy of 120Å Knees was coated on the sample using 
spatter coating unit in argon ambient of 8-10 Pascal 
with plasma voltage about 2Kv and discharge current 
about 20mA. The sputtering was done for nearly 3 
minutes to obtain uniform coating on the samples to 
enable good quality SEM images. The SEM operated 
at low accelerating voltage of about 15Kv with load 
current of about 80mA. The condenser lens position 
was maintained between 4.4-5.1. The objective lens 
aperture has a diameter of 240 µ and working dis-
tance WD = 39mm[19]. 
In-vitro dissolution studies[16] 
The method is specified in USP for drug release study 
was followed: 
Apparatus: - USP XIII dissolution rate test apparatus 
employing the round bottom dissolution vessel and 
rotating basket assembly. 
Acid stage: - 500ml of acid buffer pH 1.2. (Simulated 
gastric fluid without enzymes). 
Buffer stage: - 500ml of pH 6.8 phosphate buffer (du-
odenal fluid).  
Table 2: Formulation design of Microspheres 
S.no Formulation 
code 
Lansoprazole 
(mg) 
Cellulose acetate 
phthalate (mg) 
Liquid paraf-
fin (ml) 
Span 80 
(%) 
Drug: polymer 
Ratio 
1. F1 30 30 100 1 1:1 
2. F2 30 60 100 1 1:2 
3. F3 30 90 100 1 1:3 
4. F4 30 120 100 1 1:4 
5. F5 30 150 100 1 1:5 
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Hard gelatin capsules were filled with microspheres 
equivalent to 30mg of Lansoprazole and were evalu-
ated for in-vitro dissolution studies. The study was 
carried out in a USP rotating basket apparatus. Disso-
lution fluid consists of 500ml of simulated gastro in-
testinal fluid of increasing pH namely pH 1.2, pH 6.8 
maintained temperature at 370C±50C and the rpm 
should be at a constant speed of 75. Aliquots of sam-
ples were withdrawn after predetermined periods of 
time and the same volume of fresh medium was 
added immediately to the test medium. The with 
drawl samples were filtered through a 0.45µm mem-
brane filter. The drug content was determined in the 
filtrate after appropriate dilution and analyzed at 
284nm spectrophotometrically using Shimadzu 1201 
UV- visible spectrophotometer. Corresponding con-
centrations in the samples were calculated from 
standard plot and calculate cumulative percentage of 
drug release from each formulation. 
Drug entrapment efficiency (DEE): 
Drug entrapment efficiency of microspheres was per-
formed by accurately weighed 30mg of microspheres 
were suspended in 100ml of phosphate buffer pH6.8. 
The resulting solution was kept for 24hrs. Next day it 
was stirred for 15min and subjected for filtration. Af-
ter suitable dilution, Lansoprazole content in the fil-
trate was analyzed spectrophotometrically at 284nm 
using Shimadzu 1201 UV- visible spectrophotome-
ter[18]. 
The obtained absorbance was plotted on the stand-
ard curve to get the exact concentration of the en-
trapped drug. 
The drug entrapment efficiency was determined us-
ing following relationship:- 
% 𝐷𝐸𝐸 = (
Actual drug content
Theoretical drug content
) 𝑋100 
Kinetic treatment: 
The data obtained from the in-vitro dissolution stud-
ies subjected for kinetic treatment to obtain the order 
of release and best fit model for the formulation as 
follows: 
Zero-order model: The data obtained was plotted as 
Cumulative amount of drug released versus time. 
First order model: The data obtained was plotted as 
log cumulative percentage of drug un release versus 
time. 
Higuchi model: The data obtained was plotted as cu-
mulative percentage drug release versus square root 
of time. 
Korsmeyer - Peppas model: The data obtained was 
plotted as log cumulative percentage of drug un re-
lease versus log time. 
RESULTS AND DISCUSSION 
Drug excipient compatibility studies: 
FTIR spectrum of Lansoprasole and physical mixture 
of Lansoprasole and excipient were obtained accord-
ing to procedure given in the previous section and re-
sults were given in (Figure 3, Figure 4, Figure 5, Fig-
ure 6) and characteristic peak values were given in 
(Error! Reference source not found.). 
Table 3: FTIR spectra of physical mixture 
S.no 
Functional 
groups 
Theoretical 
value in cm-1 
Observed 
value in cm-1 
1 N-H 1306-1275 1281.47 
2 N=N & C=C 1600-1430 1455.99 
3 C-F 1400-1000 1404.03 
4 Pyridine ring 1600-1430 1579.47 
 
 
Figure 3: FTIR spectra of Lansoprazole 
 
Figure 4: FTIR spectra of Lansoprazole with span 80 
 
Figure 5: FTIR spectra of Lansoprazole with CAP 
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Figure 6: FTIR spectra of physical mixture 
Evaluation of microspheres 
Particle size analysis 
By keeping all the variables constant except polymer 
concentration, slightly increased particle size was ob-
served with the increase in polymer concentration. A 
higher concentration of polymer used in formulation 
F5 produced a more viscous dispersion, which 
formed larger droplets and consequently larger mi-
crospheres. 
Table 4: Average particle sizes of microspheres from 
F1 to F5 
Formulation code Average size (µm) 
F1 74.11±1.17 
F2 80.03±1.09 
F3 82.29±0.99 
F4 86.07±1.11 
F5 88.25±0.49 
In-vitro drug release studies 
The in-vitro dissolution studies carried out at various 
pH values (pH 1.2 and pH 6.8). Significant effect of pH 
on the release rate of Lansoprazole was observed. 
The rate of dissolution for microspheres was negligi-
ble at pH 1.2. This may be due to the enteric coating 
formed with CAP around the drug particles by means 
of microspherization. The amount of drug released 
was significantly high at higher pH values since CAP 
becomes soluble above pH 6.0. Results for in-vitro 
dissolution studies for formulation F1 to F5 were 
given in (Table 5) and the cumulative percent drug 
release graph for formulation F1 to F5 were shown in 
(Figure 7) respectively. 
Table 5: Cumulative percentage of Lansoprazole re-
lease in 0.1N HCL and pH 6.8 
S.no 
Time 
(hrs) 
Cumulative percent drug release 
F1 F2 F3 F4 F5 
1. 0 0 0 0 0 0 
2 0.25 5.41 6.52 7.77 10.61 9.44 
3. 0.5 10.02 14.93 16.54 21.83 17.97 
4. 0.75 16.52 17.83 22.18 26.35 23.73 
5. 1 20.43 22.86 26.27 32.04 28.82 
6. 2 30.24 34.65 37.74 49.22 39.91 
7. 3 33.55 38.09 40.43 56.86 47.09 
8. 4 36.83 40.55 46.15 64.31 53.16 
9. 5 39.98 45.58 52.36 71.79 61.18 
10. 6 45.41 53.52 59.28 78.96 72.15 
11. 7 52.25 61.15 66.04 84.42 77.84 
12. 8 57.08 69.53 73.38 86.21 82.18 
13. 9 64.22 74.69 79.19 90.81 88.86 
14. 10 73.93 80.48 86.75 94.27 92.23 
15. 11 87.04 85.69 89.68 94.82 93.68 
16. 12 92.8 94.55 92.72 96.34 98.65 
 
 
Figure 7: In vitro drug release profile plot of Lansopra-
zole 
Surface morphology by SEM 
The scanning electron microscopy of formulation F5 
showed that prepared microspheres have good coat-
ing and it is helpful in controlling the release of drug 
in acidic medium. Surface smoothness of Lansopra-
zole microspheres increased with increase in the pol-
ymer concentration and was confirmed by SEM. 
 
Figure 8: Scanning electron micrograph of Lansopra-
zole microspheres of formulation F5 prepared from 
Cellulose acetate phthalate 
Drug entrapment efficiency 
The entrapment efficiency of Lansoprazole micro-
sphere formulations F1 to F5 were 72.23%, 74.93%, 
79.62%, 81.37%, 88.64% respectively. It was further 
observed that the drug entrapment was proportional 
to the durg: polymer ratio and size of the Lansopra-
zole microspheres. The entrapment efficiency in-
creased with an increase in polymer concentration 
owing to the increase in the viscosity of the polymer 
solution. 
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Figure 9: Zero order plot for formulation F5 
 
Figure 10: First order plot for formulation F5 
 
Figure 11: Higuchi plot for formulation F5 
 
Figure 12: Korsemeyer-peppas plot for formulation F5 
Table 6: Kinetic results (r2 values) of formulation F5 
Formu-
lation 
code 
Zero 
order 
1st or-
der 
Higuchi 
model 
Korse-
meyer-pep-
pas model 
F5 0.9435 0.8897 0.9945 0.9144 
 
CONCLUSION  
The goal of any drug delivery system is to provide a 
therapeutic amount of drug to the proper site in the 
body and also to achieve promptly and then maintain 
the desired drug concentration over entire period of 
treatment. Microencapsulation is one of the widely 
used method for developing the new oral dosage 
form to control the drug release from the dosage 
form, improve the bioavailability, reduce adverse ef-
fects especially drug with small therapeutic range 
and prolong the action of drug. Ulcers are crater like 
sores which from in the lining of stomach, just below 
the stomach at the beginning of the small intestine in 
the duodenum. An ulcer is the result of imbalance be-
tween aggressive and defensive factors. Lansopra-
zole is a substituted benzimidazole derivative that 
targets gastric acid proton pumps, the final common 
pathway for gastric acid secretion. The drug cova-
lently binding to the proton pumps causing pro-
longed inhibition of gastric acid secretion. Formula-
tion of Lansoprazole microspheres by solvent evapo-
ration method by using CAP, with a view to prevent 
the gastric side effects and to achieve oral sustained/ 
controlled release of the drug. It is concluded that the 
polymer of choice is suitable to prepare enteric mi-
crospheres of Lansoprazole as it doesn’t interact with 
the drug to influence its pharmacological activity. The 
data suggest that a promising sustained release micro 
particulate drug delivery of lansoprazole can be de-
veloped. Our study has suggested that microencapsu-
lation by solvent evaporation technique is inexpen-
sive compared with other techniques and also ad-
vantages to prevent the drug related adverse effects 
of conventional dosage forms and maintain the sus-
tained drug release over an extended period of time.  
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